| 前收盘价格 | 0.344 |
| 收盘价格 | 0.347 |
| 成交量 | 333,836 |
| 平均成交量 (3个月) | 2,817,403 |
| 市值 | 4,969,159 |
| 市盈率 (P/E TTM) | 0.001 |
| 价格/销量 (P/S) | 0.090 |
| 股市价格/股市净资产 (P/B) | 1.04 |
| 52周波幅 | |
| 利润日期 | 18 Nov 2024 |
| 营业利益率 (TTM) | -13,497.11% |
| 稀释每股收益 (EPS TTM) | 628.80 |
| 季度收入增长率 (YOY) | -80.00% |
| 总债务/股东权益 (D/E MRQ) | 126.76% |
| 流动比率 (MRQ) | 0.070 |
| 营业现金流 (OCF TTM) | -19.59 M |
| 杠杆自由现金流 (LFCF TTM) | -13.26 M |
| 资产报酬率 (ROA TTM) | -117.61% |
| 股东权益报酬率 (ROE TTM) | -3,493.63% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Aditxt, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.17 |
|
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 0.01% |
| 机构持股比例 | 0.25% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合